Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Exp Neurol. 2016 May 18;282:49–55. doi: 10.1016/j.expneurol.2016.05.020

Figure 2. Immunoprotection mediated by sIVIg.

Figure 2

A. SNL-blot showing sialylation of Fc portion of IgGs in whole IVIg, sialyl enriched (sIVIg) and sialyl-depleted (uIVIg) IVIg fractions. B-D. Significant nerve function recovery assessed by pin prick behavior (B) and nerve conduction test (C) was found in sIVIg- and IVIg-treated animals compared to controls, which was also confirmed by morphometry (D). Note: sIVIg was given 10-fold less. E. Serial ELISA on mice sera showing that circulating anti-ganglioside mAb levels are not affected by IVIg and sIVIg treatments. C-E. *p < 0.05. N = 10 per group; Error bars, s.e.m.